NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.000.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52wk Range
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
Avg Vol (3m)N/A
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • American City Business Journals2 months ago

    Here's where Merck's new Cambridge research facility will be located

    The new microbiome research site in Cambridge planned by Merck & Co. will be at the 50,000-square-foot former facility of Idenix Pharmaceuticals, which the New Jersey-based drug giant acquired in 2014. A company spokeswoman did not say how many employees would be at the new early discovery research facility. The spokeswoman said the facilty, first reported late Tuesday , it will open in “late 2016.” The person who will oversee it — Daria Hazuda, Merck’s head of Infectious Diseases and Vaccines discovery research — will split her time between Cambridge and Merck’s facility in West Point, Pa.

  • Motley Foollast year

    3 Important Questions We Want Answered When Merck Reports Its Q2 Results

    Big Pharma Merck is scheduled to report its second-quarter earnings results on July 28. Here are three questions investors are expecting to have answered on that date.

  • CNBC2 years ago

    Activists want 'imminent retirement' of Ariad CEO

    Activist hedge fund Sarissa Capital will nominate two directors to Ariad Pharmaceuticals' board and seek the "imminent retirement" of Chief Executive Harvey Berger.